Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has filed a patent for its advanced spider silk mass production technologies, particularly focusing on knock-in knock-out gene editing systems for nearly pure spider silk fibers. This application, titled "Modification of Heavy Chain Fibrion in Bombyx Mori," builds on a provisional patent filed in February 2020. CEO Kim Thompson stated that the filing is timely as the company intends to transition this new technology to production soon, emphasizing its core role in commercialization and sales.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has successfully produced and genetically screened a new batch of spider silk silkworm eggs, ready for shipment to Vietnam to resume commercial production. Operations were halted in March due to COVID-19, during which the company enhanced its Dragon Silk strain's performance and genetics. CEO Kim Thompson praised the team's progress, emphasizing that these silkworm eggs signify the future of spider silk production.